Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function

Next Previous
X
Search
Trial Profile

Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nemonoxacin (Primary)
  • Indications Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Zhejiang Medicine

    • Most Recent Events

    • 30 Apr 2021 Results optimizing the dosing regimen in patients with severe renal impairment based on population pharmacokinetic/pharmacodynamic (PPK/PD) analysis, published in the British Journal of Clinical Pharmacology
    • 01 Apr 2018 Planned End Date changed from 1 Sep 2017 to 1 Jan 2019.
    • 01 Apr 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Jan 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top